Catalyst Tracker

04/26/2024 04:44 PM ET

ImmunityBio ABIO earnings announcement

ARCA biopharma revealed their most recent quarterly earnings data for Q1. EPS was reported to be -$0.14.

The market liked what it heard. ARCA biopharma rocketed up $0.10 (+2.87%) to $3.58 on light volume [...]

04/26/2024 04:44 PM ET

ProKidney PTCT earnings announcement

PTC Therapeutics exceeded their revenue estimate and fell in line with their EPS estimate, according to their recent quarterly earnings data. Revenue was $210.12M, exceeding estimates by 23.8%.

Not surprisingly, the [...]

04/25/2024 04:46 PM ET

Processa Pharmaceuticals BCDA date announcement

BioCardia has an announcement scheduled for December 31, 2024 regarding their recent Phase 3 trial of CardiAMP (BCDA-02). The community is currently bullish on the prospects of progression, as the bulls outnumber bears by five [...]

04/25/2024 04:46 PM ET

Elicio Therapeutics ELTX date announcement

Now that the Phase 1/2 trial of ELI-002 - (AMPLIFY-7P) is completed, Elicio Therapeutics will announce their top-line results on June 30, 2024. Our predictive system gives the drug a 60.9% chance of making it [...]

04/25/2024 04:46 PM ET

Vistagen Therapeutics VTGN results announcement

Vistagen Therapeutics provided an update to their Phase 2a trial for PH15. Our analysts provided the following summary:

"Phase 2a data reported that treatment demonstrated a statistically significant improvement in reaction time compared to placebo [...]

04/25/2024 04:46 PM ET

BeiGene Ltd. BGNE date announcement

BeiGene Ltd. already had seven catalyst announcements coming up, but they added another one today. It will be announcing top-line results for their recent Phase 1a trial for BGB‑15025 monotherapy and in combination with tislelizumab [...]

04/25/2024 04:45 PM ET

Tevogen Bio Holdings MNMD date announcement

Mind Medicine (MindMed), makers of Lysergide (LSD), will be announcing their top-line results for the drug's recent Phase 2 trial on December 31, 2024. Our calculations show a 28.6% chance that the drug makes [...]

04/25/2024 04:45 PM ET

Regeneron Pharmaceuticals REGN date announcement

Regeneron Pharmaceuticals already had 24 catalyst announcements coming up, but they added another one today. It has an announcement scheduled for June 3, 2024 regarding their recent Phase 1/2 trial of REGN7075 in combination [...]

04/25/2024 04:45 PM ET

Compugen Ltd. CGEN date announcement

Compugen Ltd., makers of COM701, COM902 and Pembrolizumab, will be announcing their top-line results for the drug's recent Phase 1 trial on December 31, 2024. Our calculations give the drug a 60.9% chance of [...]

04/25/2024 04:45 PM ET

Purple Biotech Ltd. PPBT date announcement

Purple Biotech Ltd., makers of CM24 and OPDIVO (nivolumab), will be announcing their top-line results for the drug's recent Phase 1/2 trial on May 23, 2024. Our predictive system gives the drug a 60.9% [...]

04/25/2024 04:45 PM ET

Processa Pharmaceuticals MORF earnings announcement

Morphic Holding revealed their most recent quarterly earnings data for Q1. EPS was estimated to be -$0.93 and came in right around that value at -$0.91. Morphic Holding's EPS is now above its average [...]

04/25/2024 04:45 PM ET

Sage Therapeutics SAGE earnings announcement

Sage Therapeutics exceeded their revenue estimate but fell short of their EPS estimate, according to their recent quarterly earnings data. EPS was -$1.80, missing estimates by 9.09%.

Closing price fell $0.42 [...]